Biosign Technologies Releases Scalable Architecture and Begins Shipping UFIT

Mar 31, 2011, 16:00 ET from Biosign Technologies Inc.

TORONTO, March 31 /PRNewswire/ - Biosign Technologies Inc. (TSXV: BIO, "Biosign" or the "company") is providing a corporate update on recent developments.

Biosign has successfully migrated UFIT to its proprietary "VIMIS" (Virtual Instrumentation & Measurement Information System) architecture. This new, scalable technology platform allows for each server set to process 172,800 readings per hour and store up to 2 million readings per hour.  Biosign has successfully launched the VIMIS-supported version of the UFIT Graphical User Interface and its MyUFIT.com portal. Additional features include:

  • Multi-language and regional support
  • Units of measurement by region
  • Auto-login to website
  • Multi-reading mode
  • Multi-user account mode
  • Voice recognition start and stop
  • Automatic clipboard integration

In addition to software updates, Biosign has completed an aesthetic hardware redesign for its first generation Pulse Acquisition Device "PAD" for use with UFIT TEN-10 and UFIT TEN-20. Biosign is also pleased to report it has completed prototyping and field testing of its second generation UFIT PAD with enhanced capabilities for portability and communication. The second generation PAD includes the hardware required for the measurement of Blood Pressure, Blood Glucose, Blood Oxygen, temperature and ECG (Electrocardiogram) as well as Bluetooth communication capabilities. Biosign shall provide information about ISO and other certifications of the second generation PAD when it becomes available.

As previously reported, Biosign has commenced commercial delivery to customers this quarter, and has shipped over 2500 UFIT PAD's this month. Additional details shall be provided in due course.

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

SOURCE Biosign Technologies Inc.